Clinical Trial Update: A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated ExPEC9V vaccine with and without co-administration of a high-dose quadrivalent influenza vaccine in adults aged 65 years or older, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Expec Disease

Drugs mentioned

• ExPEC9V (9-valent ExPEC vaccine)
• High-Dose Quadrivalent Influenza Vaccine (Influenza vaccine, high-dose quadrivalent)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention | Phase 3 | Status: COMPLETED | Results posted: 2026-04-03